A new study suggested that APS significantly improves cancer symptom clusters in patients with metastatic disease and reduces the expression of major proinflammatory cytokines, including IL1β, IL6, IL12, and IFNγ (Huang et al., 2019). This evidence concerns the gene IFNG and autoimmune polyendocrinopathy.